Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.

Akhmetshina, Alfiya; Dees, Clara; Pileckyte, Margarita; Maurer, Britta; Axmann, Roland; Jüngel, Astrid; Zwerina, Jochen; Gay, Steffen; Schett, Georg; Distler, Oliver; H W Distler, Jörg

doi:10.1096/fj.07-105627

Public

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.

Shared by NobleBlocks on Jul 1, 2008 • 12:00 AM UTC

Authors:

Alfiya Akhmetshina

Clara Dees

Margarita Pileckyte

Abstract

Abelson kinase (c-abl) and platelet-derived growth factor (PDGF) are key players in the pathogenesis of systemic sclerosis (SSc). The aim of the present study was to evaluate the antifibrotic potential of dasatinib and nilotinib, 2 novel inhibitors of c-abl and PDGF, which are well tolerated and hav...

Discussions